A trial looking at MDX-124 for solid tumours that have spread (ATTAINMENT)

Cancer type:

All cancer types
Pancreatic cancer




Phase 1

This trial is looking at a new drug called MDX-124 for solid tumours that have grown into surrounding tissues or spread elsewhere in the body. 

A solid tumour is any type of cancer apart from blood cancers such as leukaemia Open a glossary item and lymphoma Open a glossary item.

Cancer that has spread is advanced cancer Open a glossary item.

More about this trial

Standard treatments Open a glossary item for solid tumours include surgery, chemotherapy and radiotherapy. Sometimes cancer comes back after treatment. So doctors are looking for new treatments to give when standard treatments have stopped working for advanced cancer. 

In this trial they are looking at a drug called MDX-124. It is a type of targeted cancer drug Open a glossary item called a monoclonal antibody Open a glossary item. It targets a protein called ANXA1 that is found in higher than normal levels in many solid tumours. MDX-124 attaches to ANXA1 and stops the signals that cancer cells use to divide, grow and spread. It also helps the immune system Open a glossary item to find and kill cancer cells. 

There are 2 parts to this trial. In the first part, the team are looking at the best dose of MDX-124 to give. In the second part they are testing this dose in combination with chemotherapy for people who have pancreatic cancer. 

The main aims of the trial are to:

  • find the best dose of MDX-124 to give
  • find out how well MDX-124 works on its own and in combination with chemotherapy 
  • see how safe MDX-124 is 
  • find out what happens to MDX-124 in the body 
  • see what the side effects are

Who can enter

The following bullet points are a summary of the main entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you. 

Who can take part

You may be able to join part 1 of the trial if all of the following apply. You:

  • have a solid tumour Open a glossary item that is believed to have higher than normal levels of ANXA1 in the cancer cells. Your doctor will know which cancer types this applies to. 
  • have had standard treatment but it stopped working, you can’t have standard treatment or there isn’t a standard treatment available
  • have cancer that your doctor can measure on a scan or confirm cancer spread in a different way  

You may be able to join part 2 if all of the following apply. You:

  • have pancreatic cancer that has grown into surrounding tissues or spread elsewhere in the body 
  • are suitable to have MDX-124 in combination with chemotherapy
  • are suitable to have standard treatment with gemcitabine and nab-paclitaxel chemotherapy 
  • are not suitable to have a combination of chemotherapy called FOLFIRINOX 
  • have cancer that your doctor can measure on a scan 

As well as the entry conditions above, all of the following must apply. You: 

  • have satisfactory blood tests results
  • are fit and active but might not be able to do heavy physical work (performance status 0 or 1)
  • have a negative COVID-19 test result within 48 hours of your first dose of MDX-124
  • are willing to use reliable contraception during the trial and for a period after if there is any chance you or your partner could become pregnant 
  • are at least 18 years old

Who can’t take part
You cannot join this trial if any of these main exclusion conditions apply. 

Cancer related
You cannot join this trial if any of these apply. You:

  • have cancer of the head and neck or cervical cancer
  • have cancer that has spread to the brain or spinal cord or the membranes that surround them. Your doctor will know this.
  • have a problem with how your kidneys work 
  • have moderate to severe side effects from chemotherapy or radiotherapy. This doesn’t apply if you have numbness or tingling in your hands or feet or you have hair loss. 
  • take high doses of steroids Open a glossary item within 14 days of starting trial treatment. You can take part if you take steroids to treat inflammation of the pituitary gland Open a glossary item. Your doctor will know this. 
  • had another cancer in the past 2 years. You can take part if you had non melanoma skin cancer Open a glossary item that was successfully treated, carcinoma in situ Open a glossary item of the cervix or ductal carcinoma in situ (DCIS Open a glossary item) of the breast that was treated with the aim to cure. You can also take part if you had another cancer and you finished treatment more than a year ago and there have been no signs of it since.
  • are having another cancer treatment that isn’t a conventional medical treatment (an alternative treatment) or you take traditional Chinese Medicine 

Medical conditions
You cannot join this trial if any of these apply. You:

  • have another medical condition that isn’t controlled with medication, an active infection that needs treatment or a temperature that is higher than 38.5 C on the day you are due to have MDX-124
  • have HIV or an active hepatitis B or hepatitis C infection. You can’t take part if you have hepatitis that isn’t active and you are taking medication to treat it. 
  • have another medical condition or mental health problem that could affect you taking part 

You cannot join this trial if any of these apply. You:

  • have had a live vaccination Open a glossary item within 4 weeks of joining the trial. This doesn’t apply to approved COVID-19 vaccinations as they aren’t live. 
  • are allergic to MDX-124 or anything it contains
  • have a problem with drugs or alcohol 
  • are pregnant or breastfeeding
As well as the above there are specific exclusion criteria for each treatment group. Speak to your doctor or research nurse if you want to find out more about the entry conditions for this trial.


Trial design

This is a phase 1 trial. It is taking place in the UK. The team need up to 74 people to take part.

The trial has 2 parts:

  • finding the best dose of MDX-124 to have (part 1)
  • looking at the best dose of MDX-124 in combination with chemotherapy for people with pancreatic cancer (part 2)

Part one
The team need about 44 people to join part one. The first few people taking part have a low dose of MDX-124. The next few people have a higher dose if they don’t have any serious side effects. And so on, until doctors find the best dose. This dose is one that helps the most and has the fewest side effects. Once they find this dose, they test it in a few more people. 

Part two 
The researchers need up to 30 people with pancreatic cancer to join this part. This part is not open to recruitment yet. It will open when they find the best dose in part 1. In this part you have MDX-124 alongside chemotherapy. 

How you have treatment
Everyone has MDX-124 as a drip into a vein. It takes about 30 minutes each time. 

Everyone has MDX-124 once every 2 weeks.

Those having gemcitabine and nab-paclitaxel have it once a week for 3 weeks. You then have a week when you don’t have chemotherapy. 

You have treatment for about 7 months. You may have it for longer if treatment is still working and the side effects aren’t too bad. You stop treatment if your cancer gets worse. Your doctor will talk to you about this. 

Samples for research 
The researchers might ask you to give an extra tissue sample. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.

They plan to use the samples to:

  • measure ANXA1 in the body 
  • to see what happens to MDX-124 in the body 
  • see how well the treatment is working

You don’t have to agree to give the extra tissue sample if you don’t want to. It won’t affect you taking part in the rest of the trial. You don’t have to give all the blood samples for research either. 

Hospital visits

You see the doctor and have tests before you can take part. These include:

You have all your treatment at the hospital. You have a number of hospital visits in the first week of treatment. After that you have regular blood tests and check ups with your doctor. 

You have a CT or MRI scan at:

  • the end of month 2
  • the end of month 4 and then
  • once a month after that

You stop the trial scans if your cancer gets worse. 

You see the trial team one month after you finish treatment. They then call you every 3 months or they may see you at a routine hospital appointment. This is to see how you are getting on. 

Side effects

The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better. 

This is the first time people are having MDX-124. So there may be side effects we don’t know about yet. 

MDX-124 can affect the immune system Open a glossary item. This may cause inflammation Open a glossary item and other reactions in different parts of the body. For many people the inflammation and reactions are not too bad. For some people they can cause serious side effects. 

These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for.


The most common side effects of drugs that work in a similar way to MDX-124 include:

Other possible side effects of drugs similar to MDX-124 include:

  • a reaction that can happen within 30 minutes to 2 hours of starting treatment with MDX-124. This is called an infusion reaction. Signs include wheezing, coughing, fever, chills, sweating, low blood pressure, rash and swelling under the skin.
  • the release of a chemical in the body called cytokines (cytokine release syndrome). This happens when your immune system responds to a drug more aggressively than it should. Symptoms can include fever, feeling sick, tiredness (fatigue) and body aches.
  • inflammation of the lung
  • kidney damage 
  • liver damage

We have information about gemcitabine and nab-paclitaxel and its side effects.



Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Daniel Palmer

Supported by

Liverpool Cancer Trials Unit
Medannex Limited

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Last reviewed:

Rate this page:

Currently rated: 5 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think